Cargando…

Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria

Because of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions i...

Descripción completa

Detalles Bibliográficos
Autores principales: Joseph, Adedayo, Olatosi, Bankole, Haider, Mohammad Rifat, Adegboyega, Bolanle C., Lasebikan, Nwamaka N., Aliyu, Usman M., Ali-Gombe, Musa, Jimoh, Mutiu A., Biyi-Olutunde, Olusegun Abayomi, Awofeso, Opeyemi, Fatiregun, Omolara Aminat, Oboh, Evaristus Oseiwe, Nwachukwu, Emmanuella, Zubairu, Ismail H., Otene, Samuel A., Iyare, Oluwatoyin I., Andero, Temitope, Musbau, Alabi Babatunde, Ajose, Azeezat, Onitilo, Adedayo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853626/
https://www.ncbi.nlm.nih.gov/pubmed/35157511
http://dx.doi.org/10.1200/GO.21.00244
_version_ 1784653272644059136
author Joseph, Adedayo
Olatosi, Bankole
Haider, Mohammad Rifat
Adegboyega, Bolanle C.
Lasebikan, Nwamaka N.
Aliyu, Usman M.
Ali-Gombe, Musa
Jimoh, Mutiu A.
Biyi-Olutunde, Olusegun Abayomi
Awofeso, Opeyemi
Fatiregun, Omolara Aminat
Oboh, Evaristus Oseiwe
Nwachukwu, Emmanuella
Zubairu, Ismail H.
Otene, Samuel A.
Iyare, Oluwatoyin I.
Andero, Temitope
Musbau, Alabi Babatunde
Ajose, Azeezat
Onitilo, Adedayo A.
author_facet Joseph, Adedayo
Olatosi, Bankole
Haider, Mohammad Rifat
Adegboyega, Bolanle C.
Lasebikan, Nwamaka N.
Aliyu, Usman M.
Ali-Gombe, Musa
Jimoh, Mutiu A.
Biyi-Olutunde, Olusegun Abayomi
Awofeso, Opeyemi
Fatiregun, Omolara Aminat
Oboh, Evaristus Oseiwe
Nwachukwu, Emmanuella
Zubairu, Ismail H.
Otene, Samuel A.
Iyare, Oluwatoyin I.
Andero, Temitope
Musbau, Alabi Babatunde
Ajose, Azeezat
Onitilo, Adedayo A.
author_sort Joseph, Adedayo
collection PubMed
description Because of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions in Nigeria, we surveyed oncology patients across selected public and private cancer treatment centers. MATERIALS AND METHODS: Participating in the study were 15 tertiary cancer treatment centers across 12 Nigerian states. We recruited adult patients with cancer (18+ years) on active treatment to complete a self-administered survey on cancer care during COVID-19. We conducted descriptive and multivariate data analysis using Stata 16.1. RESULTS: Respondents were (n = 1,072), female (65.7%), ages 18-49 years (50.3%), and married (80.7%). The top two cancers were breast and prostate. Overall, 17.3% of respondents reported disruptions to cancer care, and more than half (51.0%) reported difficulties accessing care. Changes in chemotherapy regimens or route of administration were reported in 8.4% of respondents. Odds for any disruption were highest for older patients, western states, patients with prostate cancer, and patients with two or more flu symptoms. Odds for radiotherapy cancellation were highest for older patients, those with prostate cancer, and those with medium service perception. CONCLUSION: This study investigated COVID-19–influenced cancer treatment disruptions in Nigeria. Patients with cancer experienced significant disruptions to cancer care. Vulnerable patients are most likely to be negatively affected. Policies and strategies aimed at minimizing service disruptions while maintaining cancer patients' safety should be a priority for all health care institutions in the COVID-19 era.
format Online
Article
Text
id pubmed-8853626
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-88536262022-02-18 Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria Joseph, Adedayo Olatosi, Bankole Haider, Mohammad Rifat Adegboyega, Bolanle C. Lasebikan, Nwamaka N. Aliyu, Usman M. Ali-Gombe, Musa Jimoh, Mutiu A. Biyi-Olutunde, Olusegun Abayomi Awofeso, Opeyemi Fatiregun, Omolara Aminat Oboh, Evaristus Oseiwe Nwachukwu, Emmanuella Zubairu, Ismail H. Otene, Samuel A. Iyare, Oluwatoyin I. Andero, Temitope Musbau, Alabi Babatunde Ajose, Azeezat Onitilo, Adedayo A. JCO Glob Oncol ORIGINAL REPORTS Because of the global COVID-19 pandemic, health care organizations introduced guidelines for modifications to health and cancer medical care delivery to mitigate transmission and ensure quality health outcomes. To examine the extent and impact of these modifications on oncology service disruptions in Nigeria, we surveyed oncology patients across selected public and private cancer treatment centers. MATERIALS AND METHODS: Participating in the study were 15 tertiary cancer treatment centers across 12 Nigerian states. We recruited adult patients with cancer (18+ years) on active treatment to complete a self-administered survey on cancer care during COVID-19. We conducted descriptive and multivariate data analysis using Stata 16.1. RESULTS: Respondents were (n = 1,072), female (65.7%), ages 18-49 years (50.3%), and married (80.7%). The top two cancers were breast and prostate. Overall, 17.3% of respondents reported disruptions to cancer care, and more than half (51.0%) reported difficulties accessing care. Changes in chemotherapy regimens or route of administration were reported in 8.4% of respondents. Odds for any disruption were highest for older patients, western states, patients with prostate cancer, and patients with two or more flu symptoms. Odds for radiotherapy cancellation were highest for older patients, those with prostate cancer, and those with medium service perception. CONCLUSION: This study investigated COVID-19–influenced cancer treatment disruptions in Nigeria. Patients with cancer experienced significant disruptions to cancer care. Vulnerable patients are most likely to be negatively affected. Policies and strategies aimed at minimizing service disruptions while maintaining cancer patients' safety should be a priority for all health care institutions in the COVID-19 era. Wolters Kluwer Health 2022-02-14 /pmc/articles/PMC8853626/ /pubmed/35157511 http://dx.doi.org/10.1200/GO.21.00244 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License: http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle ORIGINAL REPORTS
Joseph, Adedayo
Olatosi, Bankole
Haider, Mohammad Rifat
Adegboyega, Bolanle C.
Lasebikan, Nwamaka N.
Aliyu, Usman M.
Ali-Gombe, Musa
Jimoh, Mutiu A.
Biyi-Olutunde, Olusegun Abayomi
Awofeso, Opeyemi
Fatiregun, Omolara Aminat
Oboh, Evaristus Oseiwe
Nwachukwu, Emmanuella
Zubairu, Ismail H.
Otene, Samuel A.
Iyare, Oluwatoyin I.
Andero, Temitope
Musbau, Alabi Babatunde
Ajose, Azeezat
Onitilo, Adedayo A.
Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria
title Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria
title_full Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria
title_fullStr Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria
title_full_unstemmed Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria
title_short Patient's Perspective on the Impact of COVID-19 on Cancer Treatment in Nigeria
title_sort patient's perspective on the impact of covid-19 on cancer treatment in nigeria
topic ORIGINAL REPORTS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853626/
https://www.ncbi.nlm.nih.gov/pubmed/35157511
http://dx.doi.org/10.1200/GO.21.00244
work_keys_str_mv AT josephadedayo patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT olatosibankole patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT haidermohammadrifat patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT adegboyegabolanlec patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT lasebikannwamakan patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT aliyuusmanm patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT aligombemusa patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT jimohmutiua patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT biyiolutundeolusegunabayomi patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT awofesoopeyemi patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT fatiregunomolaraaminat patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT obohevaristusoseiwe patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT nwachukwuemmanuella patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT zubairuismailh patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT otenesamuela patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT iyareoluwatoyini patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT anderotemitope patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT musbaualabibabatunde patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT ajoseazeezat patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria
AT onitiloadedayoa patientsperspectiveontheimpactofcovid19oncancertreatmentinnigeria